Oxford BioMedica PLC Board Changes, Nick Rodgers New Chairman
Published: Mar 21, 2011
The Company expresses its deep gratitude to Dr Kingsman for his invaluable contribution to the Company over the last 15 years. Dr Kingsman will continue to be a consultant to Oxford BioMedica.
For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer
Tel: +44 (0)1865 783 000
Media Enquiries: Emma Thompson/Amber Bielecka/Katja Toon M:Communications
Tel: +44 (0)20 7920 2342
1. Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene- based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Further information is available at www.oxfordbiomedica.co.uk.